Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose? DOI Open Access
Laura Marina Calabrese, Martina D’Onghia,

Laura Lazzeri

et al.

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(7), P. 775 - 775

Published: July 22, 2024

Atopic dermatitis (AD) is an immune-mediated skin disorder with a chronic-relapsing course and multifactorial pathogenesis. In contrast to the traditional concept of AD as solely type 2 immune-activated disease, new findings highlight disease highly heterogeneous, it can be classified into variable phenotypes based on clinical/epidemiological or molecular parameters. For many years, only therapeutic option for moderate–severe was immunosuppressive drugs. Recently, area systemic therapy has significantly flourished, substances are now marketed, licensed, in last step clinical development. Biological agents small molecules have enriched armamentarium moderate-to-severe AD, such dupilumab, tralokinumab, lebrikizumab (monoclonal antibodies targeting IL-4/13 pathway), abrocitinib, upadacitinib, baricitinib (JAK inhibitors). Indeed, treatment paradigm split two main approaches: axis JAK/STAT pathway. Both approaches valid strong evidence preclinical efficacy. Therefore, choice between often difficult represents major challenge dermatologists. several important factors must taken account, heterogeneity its classification phenotypes, patients’ comorbidities, age, personal preferences. The aim our review provide overview heterogeneities explore parameters that, practice, may help inform decision-making.

Language: Английский

Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose? DOI Open Access
Laura Marina Calabrese, Martina D’Onghia,

Laura Lazzeri

et al.

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(7), P. 775 - 775

Published: July 22, 2024

Atopic dermatitis (AD) is an immune-mediated skin disorder with a chronic-relapsing course and multifactorial pathogenesis. In contrast to the traditional concept of AD as solely type 2 immune-activated disease, new findings highlight disease highly heterogeneous, it can be classified into variable phenotypes based on clinical/epidemiological or molecular parameters. For many years, only therapeutic option for moderate–severe was immunosuppressive drugs. Recently, area systemic therapy has significantly flourished, substances are now marketed, licensed, in last step clinical development. Biological agents small molecules have enriched armamentarium moderate-to-severe AD, such dupilumab, tralokinumab, lebrikizumab (monoclonal antibodies targeting IL-4/13 pathway), abrocitinib, upadacitinib, baricitinib (JAK inhibitors). Indeed, treatment paradigm split two main approaches: axis JAK/STAT pathway. Both approaches valid strong evidence preclinical efficacy. Therefore, choice between often difficult represents major challenge dermatologists. several important factors must taken account, heterogeneity its classification phenotypes, patients’ comorbidities, age, personal preferences. The aim our review provide overview heterogeneities explore parameters that, practice, may help inform decision-making.

Language: Английский

Citations

3